Sofia Cristóvão-Ferreira

Sofia Cristóvão-Ferreira

Auto-generated profile, based on publicly available information

Sofia Cristóvão-Ferreira

Serviço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2013 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
SCSofia Cristóvão-Ferreira
Sofia Cristóvão-Ferreira
GNGemma Navarro
Gemma Navarro
MBMarc Brugarolas
Marc Brugarolas
KPKamil Pérez-Capote
Kamil Pérez-Capote
SVSandra H. Vaz
Sandra H. Vaz
ASAna M Sebastião
Ana M Sebastião

1 November 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SVSandra H. Vaz
Sandra H. Vaz
TJTrine N. Jørgensen
Trine N. Jørgensen
SCSofia Cristóvão-Ferreira
Sofia Cristóvão-Ferreira
SDSylvie Duflot
Sylvie Duflot
JRJoaquim A. Ribeiro
Joaquim A. Ribeiro
ASAna M. Sebastião
Ana M. Sebastião
The γ-aminobutyric acid (GABA) transporters (GATs) are located in the plasma membrane of neurons and astrocytes and are responsible for termination of GABAergic transmission. It has previously been shown that brain derived neurotrophic factor (BDNF) modulates GAT-1-mediated GABA transport in nerve terminals and neuronal cultures. We now report that BDNF enhances GAT-1-mediated GABA transport in cultured astrocytes, an effect mostly due to an increase in the V(max) kinetic constant. This action involves the truncated form of the TrkB receptor (TrkB-t) coupled to a non-classic PLC-γ/PKC-δ and ERK/MAPK pathway and requires active adenosine A(2A) receptors. Transport through GAT-3 is not affected by BDNF. To elucidate if BDNF affects trafficking of GAT-1 in astrocytes, we generated and infected astrocytes with a functional mutant of the rat GAT-1 (rGAT-1) in which the hemagglutinin (HA) epitope was incorporated into the second extracellular loop. An increase in plasma membrane of HA-rGAT-1 as well as of rGAT-1 was observed when both HA-GAT-1-transduced astrocytes and rGAT-1-overexpressing astrocytes were treated with BDNF. The effect of BDNF results from inhibition of dynamin/clathrin-dependent constitutive internalization of GAT-1 rather than from facilitation of the monensin-sensitive recycling of GAT-1 molecules back to the plasma membrane. We therefore conclude that BDNF enhances the time span of GAT-1 molecules at the plasma membrane of astrocytes. BDNF may thus play an active role in the clearance of GABA from synaptic and extrasynaptic sites and in this way influence neuronal excitability.

1 May 2018 in Cell Reports
Verified
Journal Article
Open access
MCMarine Chazalon
Marine Chazalon
EPElena Paredes-Rodriguez
Elena Paredes-Rodriguez
SMStéphanie Morin
Stéphanie Morin
AMAudrey Martinez
Audrey Martinez
SCSofia Cristóvão-Ferreira
Sofia Cristóvão-Ferreira
JBJérôme Baufreton
Jérôme Baufreton
The external globus pallidus (GP) is a key GABAergic hub in the basal ganglia (BG) circuitry, a neuronal network involved in motor control. In Parkinson's disease (PD), the rate and pattern of activity of GP neurons are profoundly altered and contribute to the motor symptoms of the disease. In rodent models of PD, the striato-pallidal pathway is hyperactive, and extracellular GABA concentrations are abnormally elevated in the GP, supporting the hypothesis of an alteration of neuronal and/or glial clearance of GABA. Here, we discovered the existence of persistent GABAergic tonic inhibition in GP neurons of dopamine-depleted (DD) rodent models. We showed that glial GAT-3 transporters are downregulated while neuronal GAT-1 function remains normal in DD rodents. Finally, we showed that blocking GAT-3 activity in vivo alters the motor coordination of control rodents, suggesting that GABAergic tonic inhibition in the GP contributes to the pathophysiology of PD.

18 March 2009 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
SCSofia Cristóvão‐Ferreira
Sofia Cristóvão‐Ferreira
SVSandra H. Vaz
Sandra H. Vaz
JRJoaquim A. Ribeiro
Joaquim A. Ribeiro
ASAna M. Sebastião
Ana M. Sebastião

1 July 2008 in Brain Research
Verified
Journal Article
Closed access
SVSandra H. Vaz
Sandra H. Vaz
SCSofia Cristóvão-Ferreira
Sofia Cristóvão-Ferreira
JRJoaquim A. Ribeiro
Joaquim A. Ribeiro
ASAna M. Sebastião
Ana M. Sebastião

1 June 2021 in The Breast
Verified
Journal Article
Open access
MFMaria Alice Franzoi
Maria Alice Franzoi
RSRita Saude-Conde
Rita Saude-Conde
SFSofia Cristóvão Ferreira
Sofia Cristóvão Ferreira
DEDaniel Eiger
Daniel Eiger
AAAhmad Awada
Ahmad Awada
EAEvandro de Azambuja
Evandro de Azambuja
Although the prognosis of metastatic breast cancer (BC) has improved, some patients still develop high burden metastases or visceral crisis (VC) and polychemotherapy is commonly used in these cases. Data reporting the real effectiveness of this strategy are scanty. Therefore, the outcomes of patients with metastatic BC treated with platinum-based chemotherapy (P-ChT) at the Jules Bordet Institute during the period of January 2008 and December 2018 were retrospectively reviewed. The presence of VC was defined according to ABC 4 criteria. 441 patients were identified: visceral metastases were observed in 430 (97.5%) while 261 (59.2%) presented VC. As for metastatic BC subtype, 255 (57.8%) had ER-positive/HER2-negative, 41 (9.3%) ER-positive/HER2-positive, 34 (7.7%) ER-negative/HER2-positive and 111 (25.1%) triple-negative BC. Median number of prior treatment lines was 3.8 (0-12). Median OS with P-ChT in the entire cohort was 6.13 months. Patients with VC had lower OS than patients without VC (8.6 vs 3.7 months; p < 0.001). On multivariate analysis, the variables correlated with worse OS were hyperbilirubinemia (HR 1.90; 95% CI 1.34-2.75), ECOG ≥2 (HR 1.77; 95% CI 1.13-2.78) and ECOG ≥3 (HR 2.52; 95% CI 1.48-4.28), and >3 previous treatment lines (HR 2.27; 95% CI 1.53-3.21). Of the 261 patients with VC, 106 (40.5%) presented a resolution of the VC which correlated with better OS (9.3 vs 2.0 months, HR 0.27; 95% CI 0.21-0.36). Patients who overcome VC benefit from P-ChT with OS similar to patients without VC. In this analysis, hyperbilirubinemia, poor ECOG and >3 previous treatment lines were significant prognostic factors in the overall study population.